DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
K
Kathy Miller, MD
Primary Investigator
Overview
This clinical trial studies nivolumab and ipilimumab in treating patients with rare tumors.
Description
The purpose of this study is to evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acinar Cell Carcinoma,Adrenal Cortex Carcinoma,Adrenal Gland Pheochromocytoma,Bronchioloalveolar Carcinoma,Anal Canal Neuroendocrine Carcinoma,Anal Canal Undifferentiated Carcinoma,Appendix Mucinous Adenocarcinoma,Bladder Adenocarcinoma,Cervical A
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Patients must have histologically confirmed rare cancer and/or cancer of unknown primary, that did not have a match to a molecularly-guided therapy on EAY131 "National Cancer Institute (NCI)-Molecular Analysis for Therapy Choice (MATCH)" protocol or who progressed on molecularly-matched therapy and have no further molecularly-matched treatment recommendations per EAY131, "NCI-MATCH"
- Patients that are determined to have a rare cancer with unknown primary site are eligible provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvis
For a full list of participation criteria, please visit clinicaltrials.gov.
Additional Information:Participants will not be paid for their participation.
Updated on
18 Apr 2024.
Study ID: 1703616209 (S1609)